Coherus Oncology vs Fennec Pharmaceuticals
CHRS and FENC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CHRS and FENC compare
Fennec Pharmaceuticals is the larger company, worth 6.4 times as much as Coherus Oncology ($476M against $73.9M).
Fennec Pharmaceuticals grew revenue faster over the last twelve months (77.8% versus 61.0% for Coherus Oncology).
Fennec Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −5.5% compared with −259% at Coherus Oncology.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CHRS | FENC |
|---|---|---|
| Size and price | ||
| Market cap | $73.9M | $476M |
| Share price | $0.478 | $13.58 |
| Change, 1 year | −59.8% | 72.8% |
| Change, 5 years | −97.4% | 40.9% |
| Beta (5Y) | 0.88 | 1.89 |
| Employees | 147 | 35 |
| StockData Score | ||
| Total score | 7 | 7 |
| Valuation score | 3 (better) | 0 |
| Growth score | 2 | 2 |
| Performance score | 1 | 3 (better) |
| Health score | 1 | 2 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.5× (better) | 8.0× |
| P/B | 1.2× (better) | 11.2× |
| Fair value | $1.16 | $7.22 |
| Margin of safety | 58.8% (better) | −88.0% |
| Growth | ||
| Revenue growth (TTM) | 61.0% | 77.8% (better) |
| Revenue growth, 5Y average | −38.4% | 195% (better) |
| Net income growth (TTM) | −174% | – |
| EPS growth, 5Y average | −2.5% | – |
| Profitability | ||
| Gross margin | 68.9% | – |
| Operating margin | −312% | −1.9% (better) |
| Net margin | −259% | −5.5% (better) |
| Return on equity | −146% | −18.6% (better) |
| Financial health | ||
| Interest coverage | −17.5× | −1.2× (better) |
| Current ratio | 1.77 | 5.85 (better) |
| Altman Z-score | −12.33 | 6.06 (better) |
| Piotroski F-score | 6 (better) | 1 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 45.5% | 46.5% |
| Held by insiders | 1.3% | – |
| Insider net buying, 12 months | – | −$9.9M |
| Short interest, % of float | 8.3% | – |
Go deeper
- CHRS stock overview
- CHRS income statement
- CHRS valuation and score
- FENC stock overview
- FENC income statement
- FENC valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.